Pancreatic Cancer Research

Clinical trialNo phase (not a drug trial)Recruiting

Prospective Multicenter Study Evaluating Feasibility and Efficacy of Tumor Organoid-based Precision Medicine in Patients With Advanced Refractory Cancers

Prospective Multicenter Study Evaluating the Feasibility and Efficacy of Tumor Organoid-based Precision Medicine in Patients With Advanced Refractory Cancers

Outcome
Ongoing
Phase
No phase (not a drug trial)
Status
Recruiting
Study type
Interventional
Start
19 January 2022
Expected end
18 January 2029
Enrollment
152 participants
Sites
11
Primary outcomes
ORGANOTREAT-01: Chemogram; ORGANOTREAT-02A: Proportion of patients treated according to the chemogram tumor board (CTB)'s recommendations on the basis of their personalized chemogram.; ORGANOTREAT-02B: PFS
Sponsor type
Academic / other
Results posted
No
Last update
26 June 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

* PDOs are tridimensional multicellular structures expanded in vitro which retain the genotypic and phenotypic features of their tissue or tumor of origin. PDOs can be exposed to a panel of drugs (chemotherapy, hormonal therapy, targeted therapy) in order to study their sensitivity to each agent (or combination of agents) tested ('chemogram'). Recent studies showed that PDOs can accurately predict the response to treatment of solid tumors and could therefore inform clinical decision on the best therapeutic option for each patient. * ORGANOTREAT is a multicenter prospective study program of organoid-based precision oncology encompassing 3 studies: ORGANOTREAT-01, a pilot study restricted to advanced CRC, and ORGANOTREAT-02A and -2B, two Phase 2 studies in advanced solid cancers.

Detailed description public domain (ClinicalTrials.gov)

ORGANOTREAT-01, -02A and -02B * Patients with advanced, pretreated solid cancers will be enrolled at the beginning of a standard-of-care (SoC) treatment line to allow sufficient time for PDO (tumor-derived organoid) generation and chemogram. * A biopsy of an easily accessible tumor site will be performed. * PDO generation, culture and amplification and drug testing will be performed. * A chemogram report will be prepared. * The CTB (Chemogram Tumor Board) will make treatment recommendations based on the chemogram report. * Patients enrolled in ORGANOTREAT-01, ORGANOTREAT-02A and in the experimental arm of ORGANOTREAT-02B will be treated according to the CTB's recommendations after disease progression or unacceptable toxicity while on SoC. * Patients will be treated at the investigator's discretion until disease progression or unacceptable toxicities. Patient will be followed until death or study termination, whichever occurs first . Note : Provide, as long as necessary (without time limit) the treatments to patient is agreed by all the centers. * Patients for whom no chemogram can be obtained will be treated according to Soc